New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 31, 2014
14:41 EDTLMNX, DGX, LH, PACB, ILMN, VCYT, SQNM, QGEN, MYGN, GHDXFDA draft lab tests guidelines not as bad as feared, says Piper Jaffray
After the FDA announced it intends to issue draft guidance on regulations for lab developed tests, Piper Jaffray said the proposed guidelines appear "less onerous" than the firm initially expected. Piper added that the FDA intends to leverage existing studies in lieu of requiring additional studies, which the firm views as positive for companies with well validated offerings such as Genomic Health (GHDX), Myriad Genetics (MYGN), QIAGEN (QGEN), Sequenom (SQNM), and Veracyte (VCYT).
News For GHDX;MYGN;QGEN;SQNM;VCYT;DGX;ILMN;LH;LMNX;PACB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 3, 2016
09:19 EDTILMNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 20.7%... Oclaro (OCLR), up 8.2%... Edwards Lifesciences (EW), up 5.8%... Natural Health (NHTC), up 5.7%... Viavi Solutions (VIAV), up 2.8%. ALSO HIGHER: Conatus (CNAT), up 18.8% after the FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis... Marvell Technology (MRVL), up 3.3% after Starboard Value disclosed a 6.7% activist stake in the company... Syngenta (SYT), up 2.9% after ChemChina offers to acquire the company in a transaction valued over $43B. DOWN AFTER EARNINGS: Navios Maritime Partners (NMM), down 33.5%... National-Oilwell Varco (NOV), down 7.9%... Chipotle (CMG), down 5.7%... Yahoo (YHOO), down 1.9%... Mondelez (MDLZ), down 4.4%... Illumina (ILMN), down 4.6%... Alexion Pharmaceuticals (ALXN), down 3.5%... Merck (MRK), down fractionally.
February 2, 2016
19:22 EDTMYGNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 16.5%... Wabash National (WNC), up 9.7%... Oclaro (OCLR), up 6.8%... Myriad Genetics (MYGN), up 8%... Ultimate Software Group (ULTI), up 6.2%... Natural Health (NHTC), up 6.2%... Edwards Lifesciences (EW), up 6.2%... Viavi Solutions (VIAV), up 2.4%... Gilead Sciences (GILD), up just under 1%. DOWN AFTER EARNINGS: Match Group (MTCH), down 7.3%... Yahoo (YHOO), down 1.2%... Chipotle (CMG), down 7.1%. ALSO LOWER: Barnes & Noble (BKS), down 2.4% after General Growth (GGP) CEO Sandeep Mathrani announced that Amazon (AMZN) is going to open 300-400 brick-and-mortar bookstores.
16:34 EDTILMNIllumina sees FY16 EPS $3.55-$3.65, consensus $3.64
Subscribe for More Information
16:34 EDTILMNIllumina reports Q4 EPS 81c, consensus 82c
Reports Q4 revenue $591.5M, consensus $585.18M.
16:23 EDTPACBOn The Fly: Top stock stories for Tuesday
Stocks began the session in negative territory and remained there throughout the entire session. The early weakness was attributed to oil prices, which were down early and never recovered during the day. The losses of more than 5% brings the loss over the past two days to more than 10%, pushing WTI crude back below $30 a barrel and squashing equities in the process. Any hope that oil prices would de-couple from stock prices will have to wait another day as the two continue to move in lockstep with each other. Even a solid earnings report from tech bellwether Alphabet (GOOG) could not help the market. ECONOMIC EVENTS: In the U.S., the economic calendar was quiet. In Europe, statistics agency Eurostat reported that unemployment across the eurozone decreased by 49,000 to a total of 16.75M in December dropping the unemployment rate to its lowest since September 2011 at 10.4%. In central bank news, the Reserve Bank of Australia and Reserve Bank of India both held their benchmark interest rates steady, as expected. COMPANY NEWS: Class A shares of Alphabet (GOOGL) advanced 1.3% to $780.91 after its better than expected quarterly results were followed by analysts around Wall Street hiking their price targets for shares, including Deutsche Bank analyst Ross Sandler, who raised his target on the parent of Google to $1,080 from $900... Exxon Mobil (XOM) reported better than expected revenue and profits in the fourth quarter, but its shares slid 2.2% to $74.61 amid the renewed weakness in oil prices. Shares of fellow oil major BP (BP) plunged 8.5% to $29.02 in New York trading after reporting a steep quarterly loss, largely due to $2.6B in charges related to impairments of Upstream assets as well as restructuring... Ford (F) shares fell 4.6% after the company reporting that its U.S. sales declined 3% last month versus a year ago. Peer General Motors (GM) slid 1.5% after reporting that its U.S. sales grew 0.5% in January... Dow Chemical (DOW) jumped 5.75% to $45.03 after posting better than expected earnings and revenue. Of note, Dow CEO Andrew Liveris said he plans to transition out of the company when it completes its planned merger with DuPont (DD). MAJOR MOVERS: Among the notable gainers were Michael Kors (KORS) and Mattel (MAT), which rose nearly 24% and almost 14%, respectively, following their earnings reports. Also higher was Pacific Biosciences (PACB), which jumped 24% to $12.67 after Reuters said Roche (RHHBY) has recently approached the company to discuss a potential acquisition. Among the noteworthy losers following earnings were Integrated Device (IDTI), which fell 26.8%, ADT (ADT), which dropped 15.7%, and Royal Caribbean (RCL), which declined 15.2%. INDEXES: The Dow fell 295.64, or 1.8%, to 16,153.54, the Nasdaq lost 103.42, or 2.24%, to 4,516.95, and the S&P 500 declined 36.35, or 1.87%, to 1,903.03.
16:14 EDTQGENQIAGEN announces agreement with CosmosID Inc.
QIAGEN announced new partnerships to "enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications." The company said, "QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID Inc., to allow users of QIAGEN's CLC Genomics Workbench to access and integrate CosmosID's metagenomics analysis platform into their QIAGEN bioinformatics platform. CosmosID's platform allows users to identify and characterize microbial communities from whole genome shotgun data and to determine their relative abundance. The new plug-in expands the range of metagenomic and microbiome applications supported by QIAGEN's microbial genomics solution enabling researchers in fields such as infectious disease, animal health, agriculture, environmental and food safety to use shotgun metagenomics analysis for routine testing employing next-generation sequencing."
16:12 EDTQGENQIAGEN says 'on course' to achieve the 2016 goals
Subscribe for More Information
16:12 EDTQGENQIAGEN reports Q4 adjusted EPS 31c, consensus 32c
Subscribe for More Information
16:10 EDTMYGNMyriad Genetics sees FY16 EPS $1.63-$1.68, consensus $1.64
Sees FY16 revenue $750-$770M , consensus $759.25M.
16:09 EDTMYGNMyriad Genetics sees Q3 EPS 37c-39c, consensus 40c
Subscribe for More Information
16:07 EDTMYGNMyriad Genetics reports Q2 EPS 45c, consensus 41c
Subscribe for More Information
15:12 EDTPACBRoche approached Pacific Biosciences about possible acquisition, Reuters says
Subscribe for More Information
15:10 EDTPACBRoche approached Pacific Biosciences about possible acquisition, Reuters says
14:32 EDTILMN, MYGNNotable companies reporting after market close
Subscribe for More Information
13:11 EDTILMNIllumina technical comments ahead of earnings
Subscribe for More Information
February 1, 2016
16:11 EDTLMNXLuminex sees Q1 revenue $60M-$62M, consensus $61.9M
Subscribe for More Information
16:10 EDTLMNXLuminex sees FY16 revenue $245M-$255M, consensus $249.13M
Subscribe for More Information
16:10 EDTLMNXLuminex reports Q4 adjusted EPS 56c vs. 19c a year ago
Reports Q4 revenue $60.4M, consensus $60.2M.
15:21 EDTILMNIllumina volatility elevated into Q4 and outlook
Illumina February weekly call option implied volatility is at 84, February is at 54, March is at 45; compared to its 52-week range of 22 to 64, suggesting large near term price movement into the expected release of Q4 results on February 2.
06:33 EDTILMNIllumina signs four biobanking deals
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use